Akebia Therapeutics, Inc. (AKBA) stock price moved -9.30% away from 20-Days Simple Moving Average, -3.09% from 50-Days Simple Moving Average and separated -9.48% from 200 Days Simple Moving Average. Akebia Therapeutics, Inc. (AKBA) reported gain 1.57% in recent buying and selling session with closing price of $ 7.13. The stock’s traded 0.9 million shares in session while it holds an average volume of 1.18 million shares. The AKBA switched 37.12% away from its 52 week minimum and distanced -38.53% from its 52 week peak. The volatility change in the previous week has observed by 5.18% and experienced of 6.25% change in the last month.
The short ratio in the company’s stock is documented at 6.12 and the short float is around of 6.72%. Beta factor, which measures the riskiness of the security, was registered at 1.46. The Company kept a record of 107.49 million floated shares and 114.49 million shares outstanding. The average true range of the stock is observed at 0.48 and the relative strength index of the stock is recorded at 43.76.
Analyst notified mean rating at 2.20 after consensus analysis. (Rating Scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Keep in mind that Investors should not rely only on an analyst’s recommendation when taking a decision whether to buy, hold, or sell a stock. Instead, they should also do their own research—such as reading the prospectus for new companies or for public companies, the quarterly and annual reports filed with the SEC—to confirm whether a particular investment is appropriate for them in light of their individual financial circumstances.
Akebia Therapeutics, Inc. (AKBA) Stock Profitability Levels:
Net profit margin of the company is seen at -69.10%. Operating profit margin is positioned at -85.70%. Gross profit margin is 97.00%. The larger the gross profit margin, the better for the company. The company made Return on equity of -50.30% in last 12 months period. Return on assets ratio of the Company was -25.40%. Its return on investment ratio was -23.00% in the trailing 12 months period.
For the past 5 years, The Company’s EPS growth has been nearly 8.10%.Analyst established EPS growth expected to grow of -46.10% for this year and EPS growth for next year is likely to attain at 42.50%.
Looking about the past performance history, the company jumped -4.42% for the last five trades and exhausted -12.73% in one month period. The stock augmented 16.12% during the past three month period and discounted -18.23% in half year. During the yearly overview it downgraded -28.34% and shown 28.93% year to date performance.